Nature packs away carbon in chalk, shells and rocks made by marine organisms that crystallize calcium carbonate. Now, research suggests that the soft, organic scaffolds in which such crystals form guide crystallization by soaking up the calcium like an "ion sponge," according to new work in Nature Materials. Understanding the process better may help researchers develop advanced materials for energy and environmental uses, such as for removing carbon dioxide from the atmosphere.
Therapeutic oligonucleotide analogs represent a new and promising family of drugs that act on nucleic acid targets such as RNA or DNA; however, their effectiveness has been limited due to difficulty crossing the cell membrane.
Joshua Zide, associate professor of materials science and engineering at the University of Delaware, has won the 2014 Peter Mark Memorial Award from AVS, an interdisciplinary society for materials, interface and processing technology.
Aehr Test Systems, a worldwide supplier of semiconductor test and burn-in equipment, today announced a purchase order from a leading IC manufacturer for a custom FOX Multi-Wafer Test System WaferPakTM Contactor and evaluation activities that will enable the manufacturer to qualify Aehr Test's next-generation FOX-XP multi-wafer system and FOX WaferPakTM Contactor for production test and burn-in of its devices.
Researchers belonging to the University of Pennsylvania, the University of Illinois at Urbana-Champaign and University of California, Berkeley have demonstrated a new method for changing the quantity of electrons that exist in a particular region within a graphene piece. Using graphene, the team has provided a proof-of-principle for producing the basic building blocks of semiconductor devices.
By Stuart Milne
27 Jan 2015
John D. Fortner, PhD, the I-CARES Career Development Assistant Professor of energy, environmental & chemical engineering, will study new composite materials for advanced water treatment with a prestigious Faculty Early Career Development Award (CAREER) from the National Science Foundation (NSF).
As nanomachine design rapidly advances, researchers are moving from wondering if the nanomachine works to how long it will work. This is an especially important question as there are so many potential applications, for instance, for medical uses, including drug delivery, early diagnosis, disease monitoring, instrumentation, and surgery.
Three of the four most fatal cancers are caused by a protein known as Ras; either because it mutates or simply because it ends up in the wrong place at the wrong time. Ras has proven an elusive target for scientist trying to cure the deadly diseases. Now a group from the Department of Chemistry, University of Copenhagen have discovered an unknown way for RAS to find its proper place in the cell. Their discovery may lead to completely novel approaches to curing cancer.
A study led by the National University of Singapore (NUS) found that attaching chemotherapy drug Epirubicin to nanodiamonds effectively eliminates chemoresistant cancer stem cells. The findings were first published online in ACS Nano, the official journal of the American Chemical Society, in December 2014.
Industrial Nanotech, Inc., an emerging global leader in nanotechnology based energy saving solutions, today announced that the Company’s patented thermal insulation and protective coatings are now being used as an OEM (original equipment manufacturer) upgrade application on new textile machinery.
Theoretical physicists at Rice University are living on the edge as they study the astounding properties of graphene. In a new study, they figure out how researchers can fracture graphene nanoribbons to get the edges they need for applications.
With its high electrical conductivity and optical transparency, indium tin oxide is one of the most widely used materials for touchscreens, plasma displays, and flexible electronics. But its rapidly escalating price has forced the electronics industry to search for other alternatives.
BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, announced today that it has entered into an amendment of its existing credit facility from Hercules Technology III, L.P., an affiliate of Hercules Technology Growth Capital. Under the amendment, the company borrowed an additional $15 million in growth capital, less the repayment of the outstanding balance on BIND’s existing term loan facility of approximately $3 million.
Michael Liehr, Executive Vice President of Innovation and Technology at the State University of New York (SUNY) Polytechnic Institute, will give a talk at 10 a.m. Friday, Jan. 30, in Room 1065 of Kemper Hall on the UC Davis campus. The event is hosted by S.J. Ben Yoo, a professor in the UC Davis Department of Electrical and Computer Engineering. The talk is presented as part of the College of Engineering’s Distinguished Lecture Series.
Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for ABRAXANE® (paclitaxel formulated as albumin-bound nanoparticles, or nab-paclitaxel) in combination with carboplatin for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.